LXRE_Luc Citations (1)

Originally described in: Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists.
Griffett K, Hayes M, Bedia-Diaz G, Appourchaux K, Sanders R, Boeckman MP, Koelblen T, Zhang J, Schulman IG, Elgendy B, Burris TP ACS Chem Biol. 2022 Apr 13. doi: 10.1021/acschembio.2c00057. PubMed Journal

---

Articles Citing LXRE_Luc

Articles

The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active. Sequera C, Grattarola M, Cannet F, Dobric A, Michea Veloso P, Methia M, Richelme S, El Kaoutari A, Kousteridou P, Debayle D, Kubler L, Nuciforo S, Boursier Y, Dupont M, Pizzimenti S, Barrera G, Dupuy JW, Saltel F, Heim MH, Vasseur S, Adhoute X, Guillaumond F, Borg JP, Morel C, Maina F. Nat Commun. 2025 Aug 25;16(1):7919. doi: 10.1038/s41467-025-62934-0. PubMed

If you have published an article using this material, please email us at to have your article added to this page.